Literature DB >> 23979161

T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies.

Constanze Hess1, André Winkler, Alexandra K Lorenz, Vivien Holecska, Véronique Blanchard, Susanne Eiglmeier, Anna-Lena Schoen, Josephine Bitterling, Alexander D Stoehr, Dominique Petzold, Tim Schommartz, Maria M M Mertes, Carolin T Schoen, Ben Tiburzy, Anne Herrmann, Jörg Köhl, Rudolf A Manz, Michael P Madaio, Markus Berger, Hedda Wardemann, Marc Ehlers.   

Abstract

Antigen-specific Abs are able to enhance or suppress immune responses depending on the receptors that they bind on immune cells. Recent studies have shown that pro- or antiinflammatory effector functions of IgG Abs are also regulated through their Fc N-linked glycosylation patterns. IgG Abs that are agalactosylated (non-galactosylated) and asialylated are proinflammatory and induced by the combination of T cell-dependent (TD) protein antigens and proinflammatory costimulation. Sialylated IgG Abs, which are immunosuppressive, and Tregs are produced in the presence of TD antigens under tolerance conditions. T cell-independent (TI) B cell activation via B cell receptor (BCR) crosslinking through polysaccharides or via BCR and TLR costimulation also induces IgG Abs, but the Fc glycosylation state of these Abs is unknown. We found in mouse experiments that TI immune responses induced suppressive sialylated IgGs, in contrast to TD proinflammatory Th1 and Th17 immune responses, which induced agalactosylated and asialylated IgGs. Transfer of low amounts of antigen-specific sialylated IgG Abs was sufficient to inhibit B cell activation and pathogenic immune reactions. These findings suggest an immune regulatory function for TI immune responses through the generation of immunosuppressive sialylated IgGs and may provide insight on the role of TI immune responses during infection, vaccination, and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979161      PMCID: PMC3754242          DOI: 10.1172/JCI65938

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  66 in total

1.  CD22 serves as a receptor for soluble IgM.

Authors:  Takahiro Adachi; Satoru Harumiya; Hiromu Takematsu; Yasunori Kozutsumi; Matthias Wabl; Manabu Fujimoto; Thomas F Tedder
Journal:  Eur J Immunol       Date:  2011-11-10       Impact factor: 5.532

2.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

3.  Identification of a receptor required for the anti-inflammatory activity of IVIG.

Authors:  Robert M Anthony; Fredrik Wermeling; Mikael C I Karlsson; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

4.  Agalactosyl IgG and antibody specificity in rheumatoid arthritis, tuberculosis, systemic lupus erythematosus and myasthenia gravis.

Authors:  C Pilkington; E Yeung; D Isenberg; A K Lefvert; G A Rook
Journal:  Autoimmunity       Date:  1995       Impact factor: 2.815

Review 5.  The impact of glycosylation on the biological function and structure of human immunoglobulins.

Authors:  James N Arnold; Mark R Wormald; Robert B Sim; Pauline M Rudd; Raymond A Dwek
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

6.  Regulation of thymus-independent responses: unresponsiveness to a second challenge of TNP-Ficoll is mediated by hapten-specific antibodies.

Authors:  P H Brodeur; H H Wortis
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

7.  Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells.

Authors:  X Dong; W J Storkus; R D Salter
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

8.  Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice.

Authors:  T Takai; M Ono; M Hikida; H Ohmori; J V Ravetch
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

9.  T cell-independent spontaneous loss of tolerance by anti-double-stranded DNA B cells in C57BL/6 mice.

Authors:  Patricia Y Tsao; Jing Jiao; Mei Qing Ji; Philip L Cohen; Robert A Eisenberg
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

10.  Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity.

Authors:  R B Parekh; I M Roitt; D A Isenberg; R A Dwek; B M Ansell; T W Rademacher
Journal:  Lancet       Date:  1988-04-30       Impact factor: 79.321

View more
  59 in total

1.  Serum N-glycan profiling can predict biopsy-proven graft rejection after living kidney transplantation.

Authors:  Osamu Soma; Shingo Hatakeyama; Tohru Yoneyama; Mitsuru Saito; Hideo Sasaki; Yuki Tobisawa; Daisuke Noro; Yuichiro Suzuki; Masakazu Tanaka; Shin-Ichiro Nishimura; Hiroshi Harada; Hideki Ishida; Kazunari Tanabe; Shigeru Satoh; Chikara Ohyama
Journal:  Clin Exp Nephrol       Date:  2019-11-25       Impact factor: 2.801

2.  Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.

Authors:  Benjamin M Fiebiger; Jad Maamary; Andrew Pincetic; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

3.  Protection by natural IgG: a sweet partnership with soluble lectins does the trick!

Authors:  Irene Puga; Andrea Cerutti
Journal:  EMBO J       Date:  2013-10-25       Impact factor: 11.598

Review 4.  Regulation of antibody effector functions through IgG Fc N-glycosylation.

Authors:  Isaak Quast; Benjamin Peschke; Jan D Lünemann
Journal:  Cell Mol Life Sci       Date:  2016-09-17       Impact factor: 9.261

Review 5.  Fc glycan-modulated immunoglobulin G effector functions.

Authors:  Isaak Quast; Jan D Lünemann
Journal:  J Clin Immunol       Date:  2014-04-24       Impact factor: 8.317

6.  Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation.

Authors:  I Schwab; F Nimmerjahn
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 7.  Type I and type II Fc receptors regulate innate and adaptive immunity.

Authors:  Andrew Pincetic; Stylianos Bournazos; David J DiLillo; Jad Maamary; Taia T Wang; Rony Dahan; Benjamin-Maximillian Fiebiger; Jeffrey V Ravetch
Journal:  Nat Immunol       Date:  2014-08       Impact factor: 25.606

8.  Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions.

Authors:  Alexandra Epp; Juliane Hobusch; Yannic C Bartsch; Janina Petry; Gina-Maria Lilienthal; Carolien A M Koeleman; Simon Eschweiler; Christian Möbs; Ashley Hall; Suzanne C Morris; Dominique Braumann; Christine Engellenner; Josephine Bitterling; Johann Rahmöller; Alexei Leliavski; Robina Thurmann; Mattias Collin; Kelley W Moremen; Richard T Strait; Véronique Blanchard; Arnd Petersen; Timo Gemoll; Jens K Habermann; Frank Petersen; Andreas Nandy; Helga Kahlert; Michael Hertl; Manfred Wuhrer; Wolfgang Pfützner; Uta Jappe; Fred D Finkelman; Marc Ehlers
Journal:  J Allergy Clin Immunol       Date:  2017-07-18       Impact factor: 10.793

Review 9.  Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?

Authors:  Michaela Seeling; Christin Brückner; Falk Nimmerjahn
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

10.  CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens.

Authors:  Karen M Haas; Kristen L Johnson; James P Phipps; Cardinal Do
Journal:  J Immunol       Date:  2018-01-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.